Dissolution of Corbion PURASORB PDL 20 at 15.0% w/v in dichloromethane creates the dispersed phase for an oil-in-water solvent-extraction microencapsulation route used in injectable sustained-release depots. The grade is an amorphous racemic D,L-lactide copolymer with a nominal inherent viscosity of 0.20 dL/g when measured at 0.1% w/v in chloroform at 25 °C. The low molecular mass reduces the terminal sterilization heat input required for depot powders and shortens the hydrolytic degradation lag relative to higher-inherent-viscosity PDL grades. The oil phase is filtered through a 0.2 µm PTFE membrane and combined with active pharmaceutical ingredient at a drug:polymer mass ratio of 1:5 to 1:10. Emulsification is performed in a Silverson L5M-A rotor-stator mixer at 8,000–12,000 rpm under a 0.5 bar nitrogen overlay, with a continuous phase containing 0.35% w/v poly(vinyl alcohol) and 0.9% w/v sodium chloride at 34 °C. Dichloromethane is extracted into 300 volumes of chilled water at 2 °C over 4 h. Hardened microspheres are collected on a 20 µm sieve, washed with 0.1% w/v polysorbate 80 solution, and lyophilized at a shelf temperature of −40 °C and 0.08 mbar for 48 h. Sterile filling of the lyophilized powder under ISO 13485:2016 requires control of residual moisture below 1.0% w/w because sorbed water initiates hydrolytic degradation during ambient storage. Residual dichloromethane is controlled below 600 ppm under ICH Q3C Class 2; endotoxin is controlled under USP <85>; and ISO 10993-5:2009 cytotoxicity release uses L929 cell viability not less than 70% of control. The processing window for the dispersed phase is 10–18% w/v; below 10% w/v droplet breakup is unstable, and above 18% w/v the dispersed-phase viscosity broadens the microsphere size distribution beyond a span of 2.5 on a Malvern Mastersizer 3000. Production-scale batch failure is most often observed as coalesced multi-core particles when rotor-stator heating exceeds 38 °C, causing premature dichloromethane evaporation and uncontrolled release profiles. Terminal finished product type: sterile injectable poly(DL-lactide) microsphere powder intended for reconstitution as a depot suspension.

What Processing Window Governs Use of PDL 20 as a Melt-Viscosity Reducer in Resorbable Tubing?

In melt-processed resorbable tubing, PDL 20 is metered at 15–30 wt% into a higher-molecular-mass PLGA 50:50 carrier resin. The PDL 20 fraction is vacuum-dried at 80 °C and <100 Pa for 12 h; Karl Fischer moisture after drying is held below 250 ppm because residual water drives ester-chain scission and shifts melt flow rate beyond 25% of the Certificate of Analysis value. A 16 mm co-rotating twin-screw extruder with L/D 25:1 and 120 rpm screw speed is operated with a barrel zone profile of 105/115/120/125/130 °C, followed by strand pelletizing and injection molding at melt temperature 135 °C, mold temperature 20 °C, holding pressure 600 bar, and cooling time 12 s. Melt viscosity reduction is measured by ISO 1133-1:2022 at 140 °C with 2.16 kg load; blends containing 20–30 wt% PDL 20 show a 30–50% increase in melt mass-flow rate relative to unmodified PLGA 50:50. Below 10 wt% PDL 20 the processing temperature reduction is insufficient to prevent thermal discoloration; above 40 wt% the extrudate lacks melt strength and tube wall thickness variation exceeds ±0.05 mm under vacuum calibration. On production lines, pelletizer filament breakage occurs when PDL 20 content exceeds 35 wt% because melt tension falls below the minimum required for strand haul-off; the failure presents as intermittent pellet size variation rather than an extruder torque alarm.

Vacuum sizing of tubing made from 15 wt% PDL 20 blends requires a calibrator inlet temperature below 40 °C and a water circulation rate sufficient to prevent surface micro-cracking. Hydrolytic stability of the finished tubing is evaluated in phosphate-buffered saline at 37 °C and pH 7.4 according to ASTM F1635-16, with exact mass-loss curves established for the specific wall thickness rather than extrapolated from raw resin data. Biological evaluation follows ISO 10993-1:2018, with endpoints selected from ISO 10993-5:2009, ISO 10993-10:2021, and USP <88> Class VI as appropriate. Terminal finished product type: sterile bioresorbable tubing for short-term fluid management or tissue drainage, and clips used where bulk hydrolytic degradation within several months is clinically acceptable.

Electrospinning of PDL 20 is performed from a 9.0 wt% solution in 70:30 v/v chloroform:N,N-dimethylformamide, with solution conductivity adjusted to 5–12 µS/cm by addition of 0.01–0.05 wt% benzyltriethylammonium chloride. The conductivity range is necessary to stabilize the Taylor cone at relative humidity up to 35%; above this humidity, water absorption into the jet produces surface porosity and beaded fibers. A syringe pump feeds the solution at 0.6–1.2 mL/h through a 21G blunt stainless steel needle charged to 18–22 kV positive polarity, and fibers are collected on a grounded stainless steel drum rotating at 300–500 rpm placed 14–16 cm from the needle tip. Fiber diameter is maintained between 500 nm and 1,200 nm by adjusting polymer concentration within 7–13 wt%; concentrations above 13 wt% induce solvent fusion and bead defects, while concentrations below 7 wt% reduce chain entanglement and lower fiber tensile strength. The collected nonwoven mats are vacuum-dried at 40 °C and 0.1 mbar for 48 h, followed by a 70% ethanolic rinse for 60 min to reduce endotoxin load and residual conductive salt. Residual chloroform is limited to 60 ppm and residual N,N-dimethylformamide to 880 ppm under ICH Q3C(R8) Class 2. Porosity of the scaffold is measured by mercury intrusion porosimetry, with targeted void volume of 80–90% and pore diameter distribution between 2 µm and 15 µm depending on fiber diameter. Biological evaluation includes ISO 10993-5:2009 cytotoxicity, ISO 10993-10:2021 skin sensitization, and ISO 10993-6:2016 local effects after implantation. Published data for this specific grade in a GMP electrospinning cell is limited; therefore process characterization lots should include scanning electron microscopy at five sampling locations and tensile testing adapted to nonwoven sheet geometry. Terminal finished product type: sterile electrospun nanofibrous scaffold sheets for soft tissue reinforcement where high porosity and temporary mechanical support are required.

Solvent-Cast Barrier Film Production Requires a Linear Drying Ramp Below the Glass Transition Temperature

PURASORB PDL 20 is dissolved at 6–10 wt% in acetone or ethyl acetate for casting of absorbable anti-adhesion films. The solution is degassed under 150 mbar vacuum for 30 min and filtered through a 0.45 µm polypropylene membrane before being applied with a motorized doctor blade onto a PTFE-coated glass plate. A wet-gap setting of 300–600 µm and traverse speed of 25 mm/s produce a uniform wet layer that is dried in a nitrogen-purged oven at an initial temperature of 30 °C, with a linear ramp of 0.5 °C/min to 45 °C and a final vacuum step at 0.1 mbar for 12 h. The dry film thickness is controlled between 0.05 mm and 0.20 mm; thickness variability across a 200 mm square sheet is maintained within ±5% by gravimetric spacing. Because the amorphous poly(DL-lactide) glass transition temperature is near 50 °C, the upper drying limit is held below 45 °C to avoid film blocking and dimensional distortion. Residual acetone or ethyl acetate is controlled below 5,000 ppm under ICH Q3C(R8) Class 3. In vitro degradation is characterized by ASTM F1635-16 in phosphate-buffered saline at 37 °C and pH 7.4; tensile properties of thin sheeting are measured under ASTM D882-18. Biological evaluation follows ISO 10993-6:2016 for local implantation effects and ISO 10993-11:2017 for systemic toxicity. If terminal sterilization is performed with gamma radiation, dose justification under ISO 11137-1:2006 is required because the low-molecular-mass grade is more sensitive to radiation-induced chain scission than higher-molecular-mass poly(L-lactide). Terminal finished product type: sterile bioresorbable barrier film intended to separate opposing tissue layers during critical healing intervals.

Table 1 consolidates primary release endpoints for the representative terminal device classes. It does not replace scenario-specific biological evaluation planning under ISO 10993-1:2018.

When PDL 20 Is Spray-Coated at Concentrations Above 4.0% w/v, Film Build-Up Shifts from Conformal to Webbed

Ultrasonic nozzle spraying of PDL 20 onto an 18 mm diameter rotating mandrel is performed with a 2.5% w/v solution in ethyl acetate. A Sono-Tek nozzle at 48 kHz atomizes the solution at 0.15 mL/min; dried film thickness per pass is 0.5–1.0 µm, and total coating thickness is maintained at 8–15 µm by pass count. The polymer is co-dissolved with crystalline therapeutic agent at a drug:polymer ratio of 30:70 w/w. Between passes, filtered nitrogen at 35 °C removes solvent; final residual ethyl acetate is controlled below 5,000 ppm under ICH Q3C(R8) Class 3. Concentrations above 4.0% w/v produce stringing and webbing between the nozzle tip and substrate, measured as a 3–5× increase in surface roughness by optical profilometry. Annealing at 45 °C for 12 h after deposition reduces pinhole density per 100 mm² from more than 5 to fewer than 1. Coating adhesion is measured by cross-hatch tape test after hydration in phosphate-buffered saline at 37 °C for 24 h; detachment greater than 5% of coating area indicates insufficient substrate surface preparation. Biological evaluation for blood-contacting finished devices follows ISO 10993-4:2017; cytotoxicity is assessed under ISO 10993-5:2009. Published data for this specific configuration is limited; pilot-scale runs should therefore fix nozzle frequency, tip distance, polymer concentration, and substrate rotation speed before pass count is used as the only thickness adjustment variable. Terminal finished product type: sterile drug-eluting balloon or peripheral implant coating where rapid resorption and controlled drug release are required and the coating is not intended to confer load-bearing mechanical integrity.